ATE530066T1 - Verbindungen zur behandlung von stoffwechselstörungen - Google Patents

Verbindungen zur behandlung von stoffwechselstörungen

Info

Publication number: ATE530066T1
Authority: AT; Austria
Prior art keywords: carbon atoms; ring; alkyl; hydrogen; treatment
Prior art date: 2006-02-28

Application number

AT07757326T

Other languages

English (en)

Inventor

Shalini Sharma

Borstel Reid Von

Original Assignee

Wellstat Therapeutics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-28

Filing date

2007-02-22

Publication date

2011-11-15

2007-02-22 Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE530066T1 publication Critical patent/ATE530066T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 3
208000030159 metabolic disease Diseases 0.000 title abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 6
125000000217 alkyl group Chemical group 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
208000010706 fatty liver disease Diseases 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
-1 perfluoromethoxy Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
- A01N31/14—Ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Pregnancy & Childbirth (AREA)
Biomedical Technology (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Plant Pathology (AREA)
Dentistry (AREA)
Wood Science & Technology (AREA)
Vascular Medicine (AREA)
Environmental Sciences (AREA)
Gynecology & Obstetrics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)

AT07757326T 2006-02-28 2007-02-22 Verbindungen zur behandlung von stoffwechselstörungen ATE530066T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US77767806P	2006-02-28	2006-02-28
PCT/US2007/062574 WO2007101060A2 (en)	2006-02-28	2007-02-22	Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number	Publication Date
ATE530066T1 true ATE530066T1 (de)	2011-11-15

Family

ID=38459732

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07757326T ATE530066T1 (de)	2006-02-28	2007-02-22	Verbindungen zur behandlung von stoffwechselstörungen

Country Status (13)

Country	Link
US (2)	US20100227901A1 (de)
EP (1)	EP1988772B1 (de)
JP (1)	JP2009528375A (de)
KR (1)	KR20080098615A (de)
CN (1)	CN101394738A (de)
AT (1)	ATE530066T1 (de)
AU (1)	AU2007220868B2 (de)
CA (1)	CA2642662A1 (de)
IL (1)	IL193321A0 (de)
MX (1)	MX2008011022A (de)
NZ (1)	NZ570100A (de)
WO (1)	WO2007101060A2 (de)
ZA (1)	ZA200806444B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3489257A1 (de)	2004-07-23	2019-05-29	Acceleron Pharma Inc.	Actrii-rezeptor-polypeptide, verfahren und zusammensetzungen
EP2781222B1 (de)	2005-11-23	2017-08-02	Acceleron Pharma, Inc.	Activin-actriia antagonisten zur verwendung in der förderung von knochenwachstum
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
CN101378740A (zh) *	2006-02-02	2009-03-04	维尔斯达医疗公司	用于治疗代谢紊乱的化合物
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en)	2007-02-01	2008-08-07	Acceleron Pharma Inc.	Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh)	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (de)	2007-02-09	2019-09-11	Acceleron Pharma Inc.	Zusammensetzungen enhaltend Activin-ActRIIA-Antagonisten
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2010539236A (ja)	2007-09-18	2010-12-16	アクセルロンファーマ，インコーポレイテッド	アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
JP5496913B2 (ja) *	2008-01-15	2014-05-21	ウェルスタットセラピューティクスコーポレイション	代謝異常の治療のための化合物
TWI626945B (zh)	2008-08-14	2018-06-21	艾瑟勒朗法瑪公司	使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5912078B2 (ja)	2009-06-08	2016-04-27	アクセルロンファーマ，インコーポレイテッド	熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (de)	2009-06-12	2020-09-02	Acceleron Pharma Inc.	Verkürzte actriib-fc-fusionsproteine
WO2011056896A1 (en) *	2009-11-03	2011-05-12	Acceleron Pharma Inc.	Methods for treating fatty liver disease
EP3332796A1 (de)	2009-11-17	2018-06-13	Acceleron Pharma Inc.	Actriib-proteine und varianten davon sowie verwendungen davon zur utrophin-induktion für therapien gegen muskuläre dystrophie
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de)	2010-04-16	2011-10-20	Sanofi-Aventis Deutschland Gmbh	Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR20130132824A (ko)	2010-11-08	2013-12-05	악셀레론 파마 인코포레이티드	Actriia 결합제 및 이의 용도
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8500260B2 (en)	2011-04-27	2013-08-06	Xerox Corporation	Ink compositions incorporating substituted oxazoline compounds or substituted oxazoline derivatives
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (de)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10195249B2 (en)	2012-11-02	2019-02-05	Celgene Corporation	Activin-ActRII antagonists and uses for treating bone and other disorders
MA40008A (fr)	2014-06-13	2021-05-05	Acceleron Pharma Inc	Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr)	2014-10-09	2017-08-15	Celgene Corp	Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI730949B (zh)	2014-12-03	2021-06-21	美商西建公司	活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4824843A (en) *	1987-06-25	1989-04-25	Warner-Lambert Company	Substituted amide inhibitors of cholesterol absorption
JP3906935B2 (ja) *	1995-12-18	2007-04-18	杏林製薬株式会社	Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
US6555536B2 (en) *	2000-05-12	2003-04-29	Ortho-Mcneil Pharmaceutical, Inc.	Biologically active 4H-benzo [1,4]oxazin-3-ones
KR100965201B1 (ko) *	2001-06-12	2010-06-24	웰스테트 테라퓨틱스 코포레이션	대사 질환의 치료용 화합물
AU2003286728A1 (en) *	2002-11-01	2004-06-07	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
ES2530235T3 (es) *	2003-02-13	2015-02-27	Wellstat Therapeutics Corporation	Compuestos para el tratamiento de trastornos metabólicos
KR101127390B1 (ko) *	2003-04-15	2012-03-23	웰스태트 테러퓨틱스 코포레이션	대사 질환의 치료용 화합물
EP1618086B1 (de) *	2003-04-22	2009-12-02	Wellstat Therapeutics Corporation	Verbindungen zur behandlung von stoffwechselstörungen
WO2004098496A2 (en) *	2003-04-30	2004-11-18	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
NZ545268A (en) *	2003-08-20	2009-05-31	Wellstat Therapeutics Corp	Compounds for the treatment of metabolic disorders

2007
- 2007-02-22 US US12/279,808 patent/US20100227901A1/en not_active Abandoned
- 2007-02-22 AT AT07757326T patent/ATE530066T1/de not_active IP Right Cessation
- 2007-02-22 KR KR1020087020406A patent/KR20080098615A/ko not_active Ceased
- 2007-02-22 CN CNA2007800071537A patent/CN101394738A/zh active Pending
- 2007-02-22 JP JP2008557453A patent/JP2009528375A/ja active Pending
- 2007-02-22 EP EP07757326A patent/EP1988772B1/de not_active Not-in-force
- 2007-02-22 CA CA002642662A patent/CA2642662A1/en not_active Abandoned
- 2007-02-22 WO PCT/US2007/062574 patent/WO2007101060A2/en not_active Ceased
- 2007-02-22 MX MX2008011022A patent/MX2008011022A/es active IP Right Grant
- 2007-02-22 AU AU2007220868A patent/AU2007220868B2/en not_active Ceased
- 2007-02-22 NZ NZ570100A patent/NZ570100A/en not_active IP Right Cessation
2008
- 2008-07-24 ZA ZA200806444A patent/ZA200806444B/xx unknown
- 2008-08-07 IL IL193321A patent/IL193321A0/en unknown
2011
- 2011-08-25 US US13/217,977 patent/US20120071526A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1988772A4 (de)	2010-10-27
CA2642662A1 (en)	2007-09-07
JP2009528375A (ja)	2009-08-06
NZ570100A (en)	2011-01-28
ZA200806444B (en)	2009-05-27
EP1988772B1 (de)	2011-10-26
AU2007220868A1 (en)	2007-09-07
KR20080098615A (ko)	2008-11-11
US20100227901A1 (en)	2010-09-09
MX2008011022A (es)	2008-09-10
US20120071526A1 (en)	2012-03-22
CN101394738A (zh)	2009-03-25
EP1988772A2 (de)	2008-11-12
IL193321A0 (en)	2009-08-03
WO2007101060A2 (en)	2007-09-07
WO2007101060A3 (en)	2007-12-13
AU2007220868B2 (en)	2011-06-09

Legal Events

Date	Code	Title	Description
2012-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
IL193321A0 (en)	2009-08-03	Compounds for the treatment of metabolic disorders
WO2007087505A3 (en)	2007-12-13	Compounds for the treatment of metabolic disorders
WO2007095462A3 (en)	2008-05-02	Compounds for the treatment of metabolic disorders
CY1111310T1 (el)	2015-08-05	Ενωσεις για την αγωγη μεταβολικων διαταραχων
WO2007137008A3 (en)	2008-08-28	Compounds for the treatment of metabolic disorders
WO2004073611A3 (en)	2004-11-25	Compounds for the treatment of metabolic disorders
ATE526018T1 (de)	2011-10-15	Verbindungen zur behandlung von stoffwechselstörungen
UA95613C2 (ru)	2011-08-25	Соединения для лечения расстройсв метаболизма
WO2004093806A3 (en)	2005-04-07	Compounds for the treatment of metabolic disorders
WO2007087506A3 (en)	2007-11-22	Compounds for the treatment of metabolic disorders
WO2007117791A3 (en)	2008-08-21	Combination treatment of metabolic disorders
WO2005105732A8 (en)	2007-04-19	Substituted methyl aryl or heteroaryl amide compounds
WO2008022267A3 (en)	2008-07-03	Combination treatment for metabolic disorders
TW200604175A (en)	2006-02-01	Ortho substituted aryl or heteroaryl amide compounds
NO20003399D0 (no)	2000-06-29	<Alfa>-amionoamidderivater som er nyttige som smertestillende midler
UA88772C2 (ru)	2009-11-25	Соединения для лечения расстройств метаболизма
SI2091948T1 (sl)	2012-07-31	Novi inhibitorji glutaminil ciklaze
WO2007087504A3 (en)	2007-11-15	Compounds for the treatment of metabolic disorders
EP1868595A4 (de)	2010-06-09	Verbindungen zur behandlung von stoffwechselstörungen
WO2007092729A3 (en)	2007-12-13	Compounds for the treatment of metabolic disorders
HK1126089A (zh)	2009-08-28	代謝紊亂的組合治療